Cargando…
A modified human ELISPOT assay to detect specific responses to primary tumor cell targets
BACKGROUND: The desired outcome of cancer vaccination is to induce a potent T cell response which can specifically recognize and eliminate autologous tumor cells in vivo. Accordingly, immunological assays that demonstrate recognition of native tumor cells (tumor-specific) may be more clinically rele...
Autores principales: | Malyguine, Anatoli, Strobl, Susan L, Shafer-Weaver, Kimberly A, Ulderich, Tracy, Troke, Angela, Baseler, Michael, Kwak, Larry W, Neelapu, Sattva S |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC415560/ https://www.ncbi.nlm.nih.gov/pubmed/15050026 http://dx.doi.org/10.1186/1479-5876-2-9 |
Ejemplares similares
-
The Granzyme B ELISPOT assay: an alternative to the (51)Cr-release assay for monitoring cell-mediated cytotoxicity
por: Shafer-Weaver, Kimberly, et al.
Publicado: (2003) -
Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay
por: Shafer-Weaver, Kimberly A, et al.
Publicado: (2004) -
Modified ELISPOT: Modifications of the Elispot Assay for T Cell Monitoring in Cancer Vaccine Trials
por: Malyguine, Anatoli
Publicado: (2005) -
ELISPOT Assay for Monitoring Cytotoxic T Lymphocytes (CTL) Activity in Cancer Vaccine Clinical Trials
por: Malyguine, Anatoli M., et al.
Publicado: (2012) -
Novel sporozoite-based ELISpot assay to assess frequency of parasite-specific B cells after vaccination with irradiated sporozoites
por: Atre, Tanmaya, et al.
Publicado: (2019)